Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Nastoupil LJ"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 27
Tytuł:
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
Autorzy:
Oncale MB
Maymani H
Nastoupil LJ
Pokaż więcej
Temat:
Hodgkin lymphoma
programmed death-1
Nivolumab
pembrolizumab
lymphoma
Diseases of the blood and blood-forming organs
RC633-647.5
Źródło:
Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 7, Pp 1-7 (2017)
Opis pliku:
electronic resource
Relacje:
https://www.dovepress.com/harnessing-the-immune-system-through-programmed-death-1-blockade-in-th-peer-reviewed-article-BLCTT; https://doaj.org/toc/1179-9889
Dostęp URL:
https://doaj.org/article/0ba68679533d455ca73fb5c9cf5a71ab  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
Autorzy:
Flowers CR
Nastoupil LJ
Sinha R
Pokaż więcej
Temat:
Diseases of the blood and blood-forming organs
RC633-647.5
Źródło:
Blood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 87-98 (2012)
Opis pliku:
electronic resource
Relacje:
http://www.dovepress.com/treatment-strategies-for-patients-with-diffuse-large-b-cell-lymphoma-p-a9731; https://doaj.org/toc/1179-9889
Dostęp URL:
https://doaj.org/article/d795dab86a484013bc53244922df03a8  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Autorzy:
Cherng HJ; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chuang HH; Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steiner R; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fayad L; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Strati P; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nair R; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hagemeister F; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lee HJ; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Flowers CR; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samaniego F; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rodriguez M; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Macapinlac HA; Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Feng L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Westin J; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Jan; Vol. 63 (1), pp. 74-83. Date of Electronic Publication: 2021 Aug 26.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/diagnostic imaging
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Positron Emission Tomography Computed Tomography*
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Fluorodeoxyglucose F18 ; Humans ; Pilot Projects ; Prospective Studies ; Salvage Therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.
Autorzy:
Nastoupil LJ; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Davis RE; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Samaniego F; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Fowler NH; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Westin J; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Lee HJ; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Wang M; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Hagemeister F; Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Cecil ARL; Karus Therapeutics Ltd., Harwell, UK.
Dow J; Karus Therapeutics Ltd., Harwell, UK.
Haque K; Karus Therapeutics Ltd., Harwell, UK.
Silva FA; Karus Therapeutics Ltd., Harwell, UK.
Whale A; Karus Therapeutics Ltd., Harwell, UK.
Lensun L; Karus Therapeutics Ltd., Harwell, UK.
Bone EA; Karus Therapeutics Ltd., Harwell, UK.
McElwaine-Johnn H; Karus Therapeutics Ltd., Harwell, UK.
Beer PA; Karus Therapeutics Ltd., Harwell, UK.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (14), pp. 3452-3462. Date of Electronic Publication: 2021 Aug 09.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, B-Cell*/drug therapy
Lymphoma, Follicular*/drug therapy
Lymphoma, Non-Hodgkin*/pathology
Aged ; Angiogenesis Inhibitors/therapeutic use ; Humans ; Phosphatidylinositol 3-Kinases ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
Autorzy:
Al Feghali KA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fang P; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gule-Monroe M; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Milgrom S; University of Colorado Cancer Center, Aurora, CO, USA.
Khoury JD; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gunther JR; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sheu T; Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Nair R; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed S; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steiner R; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Strati P; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shpall EJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nieto YL; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hosing C; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fowler N; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Flowers C; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pinnix CC; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dabaja BS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Oct; Vol. 62 (10), pp. 2400-2407. Date of Electronic Publication: 2021 May 04.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Central Nervous System Neoplasms*/drug therapy
Central Nervous System Neoplasms*/therapy
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Central Nervous System ; Humans ; Neoplasm Recurrence, Local ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.
Autorzy:
Augustyn A; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medeiros LJ; Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ludmir EB; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gunther J; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fang P; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li S; Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ok CY; Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bankston ME; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Verma V; Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA.
Pasalic D; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed S; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Strati P; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nair R; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steiner RE; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Iyer SP; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rodriguez A; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fayad LE; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Flowers CR; Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dabaja BS; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pinnix CC; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Jun; Vol. 62 (6), pp. 1361-1369. Date of Electronic Publication: 2021 Jan 22.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/therapy
Proto-Oncogene Proteins c-myc*/genetics
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Neoplasm Recurrence, Local/genetics ; Prognosis ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-6/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult.
Autorzy:
Qiu L; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Weitzman SP; Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Williams MD; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vega F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 May; Vol. 62 (5), pp. 1234-1238. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Histiocytosis*
Lung Neoplasms*
Adult ; Anaplastic Lymphoma Kinase/genetics ; Humans ; Oncogene Proteins, Fusion/genetics
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
Autorzy:
Furqan F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Watson G; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samaniego F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rashmi Kanagal-Shamanna; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Morrison MW; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thompson PA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steiner RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chi L; Department of Neuro-Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dabaja B; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (12), pp. 2980-2984. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, B-Cell, Marginal Zone*/diagnosis
Lymphoma, B-Cell, Marginal Zone*/drug therapy
Pyrimidines*/adverse effects
Adenine/analogs & derivatives ; Central Nervous System ; Humans ; Piperidines ; Pyrazoles/adverse effects
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma.
Autorzy:
Chin CK; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rodriguez MA; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qing Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Feng L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samaniego F; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jain P; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Noorani M; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fowler NH; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fayad LE; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hagemeister FB; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Flowers CR; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (12), pp. 2985-2989. Date of Electronic Publication: 2020 Jul 06.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Lymphoma, B-Cell*/drug therapy
Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Rituximab/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pretreatment SUV max may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
Autorzy:
Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samaniego F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Iyer SP; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Parmar S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steiner RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Noorani M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Davis RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fowler NH; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jun; Vol. 61 (6), pp. 1380-1387. Date of Electronic Publication: 2020 Jan 23.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Lymphoma, Follicular*/drug therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Prednisone/therapeutic use ; Prospective Studies ; Retrospective Studies ; Rituximab/therapeutic use ; Vincristine/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
Autorzy:
Hu B; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematologic Malignancies, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thakral B; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hagemeister F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samaniego F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wang ML; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fanale M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fowler N; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Feb; Vol. 61 (2), pp. 328-336. Date of Electronic Publication: 2019 Sep 18.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*/diagnosis
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Neoplasm Recurrence, Local ; Rituximab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.
Autorzy:
Sunderland AJ; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Steiner RE; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Al Zahrani M; University of British Columbia and BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.; Department of Medicine, King Saud University Hospital, Riyadh, Saudi Arabia.
Pinnix CC; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Dabaja BS; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Gunther JR; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Jerkeman M; Skånes University Hospital, Lund University, Lund, Sweden.
Joske D; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.; Department of Haematology, Pathwest Laboratory Medicine WA, Nedlands, WA, Australia.; Medical School, University of Western Australia, Crawley, WA, Australia.
Cull G; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.; Department of Haematology, Pathwest Laboratory Medicine WA, Nedlands, WA, Australia.; Medical School, University of Western Australia, Crawley, WA, Australia.
El-Galaly T; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Villa D; University of British Columbia and BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.
Cheah CY; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.; Department of Haematology, Pathwest Laboratory Medicine WA, Nedlands, WA, Australia.; Medical School, University of Western Australia, Crawley, WA, Australia.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Jan; Vol. 9 (2), pp. 663-670. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms:
Central Nervous System Neoplasms/*mortality
Dura Mater/*pathology
Lymphoma, B-Cell, Marginal Zone/*mortality
Adult ; Aged ; Central Nervous System Neoplasms/pathology ; Central Nervous System Neoplasms/therapy ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Lymphoma, B-Cell, Marginal Zone/pathology ; Lymphoma, B-Cell, Marginal Zone/therapy ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.
Autorzy:
Andraos TY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ayoub Z; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nastoupil LJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Milgrom SA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ng SP; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fowler NH; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neelapu SS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samaniego F; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fayad LE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (13), pp. 3258-3265. Date of Electronic Publication: 2019 Jun 24.
Typ publikacji:
Journal Article
MeSH Terms:
Lymph Node Excision*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Chemoradiotherapy, Adjuvant/*methods
Lymphoma, Follicular/*therapy
Adolescent ; Adult ; Aged ; Biopsy/methods ; Female ; Follow-Up Studies ; Humans ; Lymph Nodes/diagnostic imaging ; Lymph Nodes/pathology ; Lymph Nodes/surgery ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography ; Progression-Free Survival ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs.
Autorzy:
Zackon AYL; Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Ayers AA; Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Yeager KA; Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Somma ML; Scientific and Research Programs, Lymphoma Research Foundation , New York , NY , USA.
Friedberg JW; Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
Flowers CR; Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Nastoupil LJ; MD Anderson Cancer Center, The University of Texas , Houston , TX , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Oct; Vol. 60 (10), pp. 2356-2364. Date of Electronic Publication: 2019 Jun 04.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Lymphoid/*drug therapy
Lymphoma/*drug therapy
Administration, Oral ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Clinical Trials as Topic ; Humans ; Leukemia, Lymphoid/diagnosis ; Leukemia, Lymphoid/mortality ; Lymphoma/diagnosis ; Lymphoma/mortality ; Medication Adherence ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.
Autorzy:
Ayoub Z; Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Andraos T; Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Milgrom SA; Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Pinnix CC; Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Dabaja BS; Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Ng SP; Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Gunther JR; Division of Radiation Oncology, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Fowler NH; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Neelapu SS; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Samaniego F; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Fayad LE; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Nastoupil LJ; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Oct; Vol. 60 (10), pp. 2432-2440. Date of Electronic Publication: 2019 Apr 03.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Follicular/*diagnosis
Lymphoma, Follicular/*pathology
Adult ; Aged ; Biomarkers ; Combined Modality Therapy ; Disease Progression ; Female ; Humans ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms.
Autorzy:
Ludmir EB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, .
Gutschenritter T; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, .
Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, .
Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, .
Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, .
Milgrom SA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, .
Pokaż więcej
Źródło:
OncoTargets and therapy [Onco Targets Ther] 2018 Dec 10; Vol. 11, pp. 8937-8942. Date of Electronic Publication: 2018 Dec 10 (Print Publication: 2018).
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure.
Autorzy:
Ludmir EB; a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Milgrom SA; a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Pinnix CC; a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Gunther JR; a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Westin J; b Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Oki Y; b Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Fayad LE; b Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Medeiros LJ; c Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Dabaja BS; a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Nastoupil LJ; b Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2018 Dec; Vol. 59 (12), pp. 2896-2903. Date of Electronic Publication: 2018 Apr 26.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*therapy
Breast Neoplasms, Male/*therapy
Lymphoma, Large B-Cell, Diffuse/*therapy
Neoplasm Recurrence, Local/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Breast/pathology ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Breast Neoplasms, Male/mortality ; Breast Neoplasms, Male/pathology ; Central Nervous System Neoplasms/prevention & control ; Central Nervous System Neoplasms/secondary ; Chemoradiotherapy/methods ; Chemoradiotherapy/statistics & numerical data ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/prevention & control ; Progression-Free Survival ; Radiotherapy Dosage ; Retrospective Studies ; Survival Analysis ; Time Factors ; Treatment Failure
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
Autorzy:
Guidot DM; a Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Switchenko JM; b Department of Biostatistics , Emory University , Atlanta , GA , USA.
Nastoupil LJ; c MD Anderson Cancer Center, University of Texas , Houston , TX , USA.
Koff JL; a Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Blum KA; d James Comprehensive Cancer Center, The Ohio State University , Columbus , OH , USA.
Maly J; d James Comprehensive Cancer Center, The Ohio State University , Columbus , OH , USA.
Flowers CR; a Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Cohen JB; a Winship Cancer Institute, Emory University , Atlanta , GA , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2018 Apr; Vol. 59 (4), pp. 888-895. Date of Electronic Publication: 2017 Aug 10.
Typ publikacji:
Comparative Study; Evaluation Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Positron Emission Tomography Computed Tomography*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Mantle-Cell/*drug therapy
Neoplasm Recurrence, Local/*diagnostic imaging
Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Mantle-Cell/diagnostic imaging ; Lymphoma, Mantle-Cell/mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Predictive Value of Tests ; Proportional Hazards Models ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Autorzy:
Hu B; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Younes A; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Westin JR; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Turturro F; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Claret L; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Feng L; b Department of Biostatistics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Fowler N; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Neelapu S; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Romaguera J; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Hagemeister FB; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Rodriguez MA; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Samaniego F; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Fayad LE; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Copeland AR; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Nastoupil LJ; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Nieto Y; c Department of Stem Cell Transplantation , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Fanale MA; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Oki Y; a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2018 Apr; Vol. 59 (4), pp. 863-870. Date of Electronic Publication: 2017 Aug 09.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Histone Deacetylase Inhibitors/*therapeutic use
Hodgkin Disease/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Panobinostat/*therapeutic use
Adult ; Aged ; Bone Marrow/drug effects ; Carboplatin/therapeutic use ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Etoposide/therapeutic use ; Female ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/adverse effects ; Hodgkin Disease/mortality ; Hodgkin Disease/pathology ; Humans ; Ifosfamide/therapeutic use ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neutropenia/chemically induced ; Neutropenia/epidemiology ; Panobinostat/administration & dosage ; Panobinostat/adverse effects ; Survival Rate ; Thrombocytopenia/chemically induced ; Thrombocytopenia/epidemiology ; Treatment Outcome ; Young Adult
SCR Protocol:
ICE protocol 3
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 27

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies